Clinical Trial Update: Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and safety study of ceftolozane/tazobactam in pediatric patients receiving antibiotics for Gram-negative infection or peri-operative pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peri-operative Prophylaxis
• Proven or Suspected Gram-negative Bacterial Infection

Drugs mentioned

• Ceftolozane/Tazobactam (ceftolozane/tazobactam)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis | Phase 1 | Status: COMPLETED | Results posted: 2019-02-15